Cervical Intraepithelial Neoplasia is not Associated with Elevated Serum Neopterin Levels

Howard D. Strickler, Angela Manns, Mark H. Schiffman, William A. Blattner, Carlos Escoffery, Carole Rattray, Beverly Cranston, Barrie Hanchard, Dietmar Fuchs, Helmut Wachter

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Neopterin, a marker of cellular immune activation, was elevated in patients who had cervical cancer in previous studies. To examine neopterin in the presence of precursors to cervical cancer (i.e., cervical intraepithelial neoplasia) we measured serum levels in 185 colposcopy patients in Jamaica, a country with high cervical cancer incidence, and in 72 age-matched Jamaican women selected from a large population-based sample. We also measured serum levels of β-2- microglobulin, another commonly used marker of immune activation. Neopterin and β -2-microglobulin levels were not elevated in colposcopy patients; neither were they related to severity of cervical neoplasia. In multivariable analysis, neither adjustments for detection of cervical human papillomavirus DNA by PCR nor detection of antibodies to human T-cell lymphotropic virus type I (a retrovirus endemic to Jamaica) altered our findings. The absence of a serologically detectable increase in cellular immune activation linked to cervical intraepithelial neoplasia suggests that the immunological response to cervical intraepithelial neoplasia does not involve substantial systemic cellular immune activation.

Original languageEnglish (US)
Pages (from-to)295-298
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume4
Issue number3
StatePublished - Apr 1 1995
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Strickler, H. D., Manns, A., Schiffman, M. H., Blattner, W. A., Escoffery, C., Rattray, C., Cranston, B., Hanchard, B., Fuchs, D., & Wachter, H. (1995). Cervical Intraepithelial Neoplasia is not Associated with Elevated Serum Neopterin Levels. Cancer Epidemiology Biomarkers and Prevention, 4(3), 295-298.